Opinion|Videos|February 11, 2025
Pirtobrutinib in R/R CLL: Can It Be Used in the Second-Line Setting?
Panelists discuss how pirtobrutinib is increasingly being considered as a second-line option in relapsed/refractory chronic lymphocytic leukemia (R/R CLL), particularly for patients who have developed resistance or intolerance to covalent Bruton tyrosine kinase (BTK) inhibitors, though the optimal positioning of this noncovalent BTK inhibitor continues to evolve as more real-world experience accumulates.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Panelists discuss how pirtobrutinib is increasingly being considered as a second-line option in relapsed/refractory chronic lymphocytic leukemia (R/R CLL), particularly for patients who have developed resistance or intolerance to covalent Bruton tyrosine kinase (BTK) inhibitors, though the optimal positioning of this noncovalent BTK inhibitor continues to evolve as more real-world experience accumulates.
Advertisement
Related to this article
Teclistamab plus talquetamab met the primary PFS end point and improved overall survival in relapsed/refractory multiple myeloma in MonumenTAL-6.
The FDA has granted priority review to a supplemental application for talazoparib plus enzalutamide in HRR-altered mCSPC.
Camizestrant plus a CDK4/6 inhibitor was approved in the European Union for ER-positive, HER2-negative advanced breast cancer with an emergent ESR1 mutation.
The FDA is reviewing data for daraxonrasib in previously treated pancreatic cancer under the Commissioner’s National Priority Voucher program.
Johannes Schetelig, MD, MSc, discusses phase 3 data for post-transplant cyclophosphamide vs ATLG as GVHD prophylaxis in hematologic malignancies.
Matthew Galsky, MD, discusses the FDA approval of perioperative pembrolizumab plus enfortumab vedotin in MIBC.
The FDA has approved zidesamtinib in patients with locally advanced/metastatic ROS1+ NSCLC who received a prior ROS1 kinase inhibitor.
A 3-year, $225K award will focus on improving quality of life for patients living with long-term effects of cancer treatment.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
2
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
3
Dr Galsky on Systemic Therapy Advances in Muscle-Invasive Bladder Cancer
4
Dr Patel on the Unmet Need in EGFR+ Transformed Small Cell Lung Cancer
5